|All Peptides

Tesamorelin

An FDA-approved peptide for reducing stubborn visceral belly fat. Tesamorelin is the only FDA-approved GHRH analog, specifically for reducing visceral abdominal fat in HIV lipodystrophy. Uses the full 44 amino acid GHRH sequence with a trans-3-hexenoic acid modification for stability. Produces physiological GH pulses that specifically target stubborn belly fat.

Compare Prices
🧬Key Characteristics
  • Length: 44 amino acids
    (Full-length GHRH with N-terminal modification.)
  • Half-life: ~26–38 minutes
    (Longer than sermorelin due to the hexenoic acid modification.)
  • FDA Status: FDA Approved
    (Approved in 2010 for reducing excess abdominal fat.)
  • Primary Use: Visceral fat reduction
    (Specifically targets abdominal/trunk adipose tissue.)
Modified sequence
(trans-3-hexenoic acid)-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂
The trans-3-hexenoic acid modification at the N-terminus improves stability and bioavailability. FDA-approved for reducing excess abdominal fat.
Key takeaway: Tesamorelin is the only GHRH analog with FDA approval, specifically for reducing visceral (abdominal) fat. Unlike shorter fragments like Sermorelin (29 AA), Tesamorelin uses the full 44 amino acid GHRH sequence with a stabilizing modification, making it particularly effective for targeting abdominal adipose tissue.

Overview

Core Benefits

Key Advantages
Visceral fat reduction
FDA-studied to reduce trunk/abdominal fat by 15-18% in clinical trials.
Metabolic health
Associated with improved lipid profiles and cardiovascular markers in studies.
Lean mass preservation
Reduces fat while maintaining muscle tissue, improving body composition ratio.
FDA-approved
The only GHRH analog with FDA approval for a specific therapeutic indication.
Quality of life
Patients report improved energy, reduced bloating, and better self-image.
Natural GH release
Stimulates pituitary to release GH naturally, maintaining feedback mechanisms.

These are educational summaries of commonly discussed effects in wellness/regenerative contexts, not guarantees.

Tesamorelin Results Timeline

Progression
1
Week 1–2
Physical Changes
Initial visceral fat mobilization begins
Performance & Recovery
Improved sleep quality, subtle energy increase
Other Benefits
Stable mood, reduced bloating sensation
2
Week 3–4
Physical Changes
Early reduction in trunk fat, waist circumference decreases
Performance & Recovery
Better workout recovery, increased endurance
Other Benefits
Improved lipid markers beginning, mental clarity
3
Week 5–6
Physical Changes
Visible visceral fat reduction, improved body composition
Performance & Recovery
Enhanced exercise capacity, strength maintenance
Other Benefits
Cardiovascular health markers improve, sustained energy
4
Week 7–8
Physical Changes
Peak visceral fat loss for cycle (up to 15-20% in studies)
Performance & Recovery
Consistent recovery and performance benefits
Other Benefits
End of 8-week cycle; take 8 weeks off before repeating

Timeline is illustrative and non-guaranteed. Outcomes vary and are commonly discussed alongside training, nutrition, sleep, and cycling practices.

How It Works

GHRH Analog (Growth Hormone Releasing Hormone)

Sequence → Stability → GH Pattern → Outcomes

🎯
Target

GHRH Receptor on Pituitary Somatotrophs

Tesamorelin binds the same GHRH receptor as Sermorelin and CJC-1295. However, Tesamorelin uses the full 44 amino acid GHRH sequence rather than just the first 29, providing a more "native-like" signaling profile.

Cellular Signal

cAMP → PKA Cascade → Reliable GH Pulse

Same cAMP/PKA signaling cascade as other GHRH analogs. The trans-3-hexenoic acid cap at the N-terminus increases stability in the bloodstream, resulting in a more predictable and reliable stimulation window compared to shorter fragments.

🔄
Systemic Effect

Consistent GH Pulses → Visceral Fat Mobilization

The reliable GH pulse pattern has been clinically demonstrated to reduce visceral (abdominal) fat by 15-18% in trials. GH-mediated lipolysis preferentially targets visceral adipose tissue, improving lipid profiles and metabolic health markers.

What You Notice

Belly Fat Reduction → Metabolic Improvements → Vitality

Reduced abdominal circumference is the hallmark outcome, typically visible within 2-3 months. Improved energy, better lipid panels, and body composition changes follow. Tesamorelin has the strongest clinical evidence of any GHRH analog for measurable outcomes.

What Makes This Peptide Different

Tesamorelin is the only GHRH analog with FDA approval (for HIV-associated lipodystrophy). It uses the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid modification at the N-terminus. This makes it more "native-like" than the 29-AA fragments ( Sermorelin, CJC-1295) while being more stable than unmodified GHRH. Its clinical validation for visceral fat reduction sets it apart from all other GHRH peptides.

Sequence → Why It Matters

Tesamorelin is a nearly full-length GHRH analog with one key modification:

1
Full 44-AA sequence (vs 29-AA fragments)
More complete receptor engagement — closer to native GHRH signaling
2
Trans-3-hexenoic acid at N-terminus
Stability cap — protects against enzymatic degradation, extends effective half-life to ~26-38 min

So what? Being a nearly full-length analog with a stability-enhancing cap gives Tesamorelin the most predictable stimulation window among pulsatile GHRH peptides. This reliability is likely why it has the strongest clinical data for measurable outcomes — specifically visceral fat reduction.

GHRH Peptide Comparison

PeptideHalf-LifeGH PatternWhat's Unique
Sermorelin~10-20 minShort, natural pulseNative GHRH(1-29) — unmodified, shortest duration
CJC-1295 (no DAC)~30 minBroader natural pulse4 substitutions for stability — reliable signaling
Tesamorelin~26-38 minReliable, broader pulseFull 44-AA + hexenoic acid — FDA-approved for visceral fat
CJC-1295 (DAC)6-8 daysSustained elevationAlbumin binding — weekly dosing, non-pulsatile

Dosing Protocol

Fat Loss / Visceral Fat

Educational reference only. Individual responses vary. Consult healthcare provider before use.

Vial Size
10 mg
Reconstitution
2 ml BAC water
Dose
1 mg (20 units on 1ml syringe)
Timing
AM and/or PM on empty stomach
Frequency
5 days on, 2 days off
Duration
8 weeks on, 8 weeks off
Protocol Notes
Best taken on empty stomach (2+ hr fast). Particularly effective for reducing visceral (belly) fat. FDA-approved dose is 2 mg daily for lipodystrophy.

Why This Dosing Protocol

Why empty stomach? Insulin blunts GH release. Tesamorelin should be taken on an empty stomach (2+ hour fast) to maximize the GH pulse.

Why 5 days on / 2 days off? Prevents receptor desensitization and maintains consistent response quality across the protocol duration.

Why this works for visceral fat: Consistent GH pulses preferentially mobilize visceral adipose tissue. The reliable half-life means each dose hits the same signaling window, creating cumulative fat mobilization over weeks to months.

Looking for medical guidance?

Join the waitlist for doctor-guided peptide plans. We'll notify you when telehealth consultations are available in your state.

Stacks

Tesamorelin is commonly paired with ipamorelin in GH-axis research discussions. For comparing bundles fairly, we normalize stack value using the Tesamorelin amount as the driving peptide (assuming ratios remain consistent as bundle sizes scale).

Tesamorelin + Ipamorelin

Bundle of Tesamorelin (FDA-approved GHRH analog) and Ipamorelin (ghrelin-receptor secretagogue) for synergistic GH release.

Sorted by cost per mg of CJC. COA = Certificate of Analysis (vendor-provided lab documentation).
VendorStackPrice$/mg (CJC)COALink
EZ Peptides10mg/3mgNon-1:1$88.00$8.80Go →

Reconstitution calculator

Dilution math and unit conversions. Prefilled using a common vial size for this peptide.

Open calculator

Educational Videos

How to Reconstitute Peptides

Handling

Educational overview on storage, labeling, and traceability considerations for lab environments. Consult primary literature and vendor documentation for specifics.

Powder Storage (Very Stable)
  • Freezer (-20°C): 1+ year ✓
  • Refrigerator (2-8°C): 1-3 months ✓
  • Room temperature: 2-3 weeks (emergency only)
Reconstituted Storage (Fragile)
  • MUST refrigerate at 2-8°C
  • 4-week maximum shelf life
  • NEVER freeze after reconstitution
  • Use bacteriostatic water for multi-dose

Storage & Handling Guide

Learn proper storage temperatures, shelf life timelines, reconstitution best practices, and travel tips for lyophilized and reconstituted peptides.

Powder: Freezer
1+ year at -20°C
Reconstituted: Fridge
4 weeks max at 2-8°C
View Complete Storage Guide

FAQ

What makes Tesamorelin different from other GHRH peptides?

Tesamorelin is the only GHRH analog that is FDA-approved for a specific therapeutic use (reducing excess abdominal fat). It uses the full 44 amino acid GHRH sequence with a trans-3-hexenoic acid modification, giving it a longer half-life (~26-38 minutes) than sermorelin and making it particularly effective for reducing visceral (abdominal) fat.

What are the most common side effects?

In clinical trials, the most common side effects included injection site reactions (redness, itching, swelling), joint pain (arthralgia), and peripheral edema (fluid retention in extremities). Some patients also reported muscle pain and paresthesia (tingling sensations). These effects are generally mild and often decrease with continued use.

How effective is Tesamorelin for fat loss?

In FDA clinical trials, Tesamorelin reduced trunk fat by approximately 15-18% over 26 weeks. It specifically targets visceral adipose tissue (VAT) rather than subcutaneous fat, making it particularly effective for reducing dangerous abdominal fat associated with metabolic syndrome and cardiovascular risk.

Is Tesamorelin FDA-approved?

Yes. Tesamorelin was FDA-approved in November 2010 specifically for the reduction of excess abdominal fat. This makes it unique among GHRH peptides as it has undergone rigorous clinical trials and regulatory review for this specific indication.

What is the typical Tesamorelin dosage?

A common research dosage is 1 mg injected subcutaneously once daily (20 units on 1ml syringe). Best taken AM and/or PM on an empty stomach (2+ hour fast). Protocol: 5 days on, 2 days off, 8 weeks on, 8 weeks off. The FDA-approved dose for lipodystrophy is 2 mg daily.

Why does Tesamorelin target visceral fat specifically?

Growth hormone preferentially mobilizes visceral fat (deep abdominal fat around organs) over subcutaneous fat (fat under the skin). Tesamorelin's ability to increase GH levels results in selective reduction of this metabolically dangerous fat. Visceral fat is linked to insulin resistance, cardiovascular disease, and metabolic syndrome.

Can Tesamorelin be combined with other peptides?

Yes, some combine Tesamorelin with GHRPs like Ipamorelin for enhanced GH release. Others add AOD-9604 for additional fat loss effects. Since Tesamorelin is FDA-approved, it has more established safety data than most peptides, making it a foundation some build upon.

How does Tesamorelin compare to Sermorelin and CJC-1295?

Tesamorelin uses the full 44-amino acid GHRH sequence (vs 29 for Sermorelin), has a longer half-life due to its modification, and is FDA-approved. It's specifically proven for visceral fat reduction. Sermorelin and CJC-1295 are more commonly used for general GH benefits. Tesamorelin is typically more expensive but has stronger clinical validation.

How long does reconstituted peptide last?

Once mixed with bacteriostatic water, peptides remain stable for up to 4 weeks when refrigerated at 2-8°C (36-46°F). Unopened powder can last 1+ year in the freezer. Get our complete Storage & Travel Guide.

Is this peptide legal to purchase?

Peptides sold "for research purposes only" are legal to purchase in the US, but are not FDA-approved for human use outside of specific medical applications. Always consult a healthcare provider before use.

New to peptides?

Take our Peptide Match tool to find the best peptide for your goals. You can also read our Complete Guide to Peptides to learn the basics.

Scientific Sources

The following peer-reviewed studies and official resources provide additional scientific context for this peptide:

Disclosure: we may earn affiliate commission from qualifying purchases. Educational information only — not medical advice.